Lilly and QurCan enter genetic-medicine collaboration worth up to $237m per programme
Lilly and QurCan Therapeutics have entered a multi-programme collaboration to develop nucleic-acid medicines for central and peripheral nervous system diseases using QurCan's TERP delivery platform.
QurCan's polymer-lipid nanoparticle technology is designed to deliver genetic medicines beyond the liver and will be applied to selected CNS and PNS targets under the collaboration.
QurCan is eligible for up to $237 million per programme in development and commercial milestones, as well as royalties, giving the agreement potentially substantial value across multiple programmes.
Field | Content |
Alert Type | Deal |
Companies | Eli Lilly and Company; QurCan Therapeutics |
Deal Type | Strategic research and licensing collaboration |
Asset or Company | TERP polymer-lipid nanoparticle delivery platform |
Therapy Area(s) | Neurology; central nervous system; peripheral nervous system |
Technology or Modality | Nucleic-acid therapeutics; polymer-lipid nanoparticles; genetic medicine |
Deal Value | Up to US$237 million per programme in milestone payments, plus royalties |
Geography | Global |
What Happened | Lilly and QurCan Therapeutics entered a multi-programme collaboration to develop CNS and PNS genetic medicines using QurCan's TERP delivery technology. |
Why It Matters | Efficient delivery remains a major challenge for genetic medicines outside the liver, and the collaboration gives Lilly access to a platform designed for broader tissue targeting. |
Supporting Context | QurCan's TERP technology uses polymer-lipid nanoparticles designed to deliver nucleic-acid therapeutics to tissues including the central and peripheral nervous systems. |
Strategic Rationale | Lilly gains access to a specialised delivery platform while QurCan receives development funding and potential milestone and royalty economics across multiple programmes. |
Potential Impact | Successful programmes could expand the range of neurological diseases addressable with nucleic-acid medicines. |
Key Takeaway | Lilly is partnering with QurCan on multiple genetic-medicine programmes, with potential payments of up to US$237 million per programme. |
What to Watch | Selection of programme targets, preclinical development and evidence that TERP can achieve effective delivery in CNS and PNS tissues. |
Primary Source | QurCan Therapeutics |
Relevant Date | 15 September 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comentários